Design, synthesis and bioactivity evaluation of selenium-containing PI3Kδ inhibitors

PI3K6 inhibitors play an important role in the treatment of leukemia, lymphoma and autoimmune diseases. Herein, using our reported compounds as the lead compound, we designed and synthesized a series of selenium containing PI3K6 inhibitors based on quinazoline and pyrido[3,2-d]pyrimidine skeletons. Among them, compound Se15 showed sub-nanomolar inhibition against PI3K6 and strong 6 -selectivity. Moreover, Se15 showed potent anti-proliferative effect on SU-DHL-6 cells with an IC50 value of 0.16 & mu;M. Molecular docking study showed that Se15 was able to form multiple hydrogen bonds with PI3K6 and was close proximity and stacking with PI3K6 selective region. In conclusion, the Se-containing compound Se15 bearing pyrido[3,2-d]pyrimidine scaffold is a novel potent and selective PI3K6 inhibitor. The introduction of selenium can enrich the structure of PI3K6 inhibitors and provide a new idea for design of novel PI3K6 inhibitors.